<DOC>
	<DOCNO>NCT02200237</DOCNO>
	<brief_summary>This study aim evaluate safety , reactogenicity immunogenicity EV71 vaccine health child infant age 2 month &lt; 12yrs .</brief_summary>
	<brief_title>A Clinical Study Inactivated Vaccine Against EV71</brief_title>
	<detailed_description />
	<mesh_term>Enterovirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum phosphate</mesh_term>
	<criteria>Main 1 . Healthy child infant age 2 month le 12 year establish medical history clinical examination 2 . The subject ' guardian able understand sign inform consent Main 1 . Subject previous know exposure EV71 . 2 . Subject history herpangina hand , foot mouth disease associate enterovirus infection past 3 month . 3 . Subject diagnose significant neurological , pulmonary , cardiovascular , hematological , hepatic renal disorder . 4 . Use investigational/nonregistered product ( include drug , vaccine invasive medical device ) within 30 day prior vaccination plan use study period . 5 . Subject confirm suspect autoimmune disorder , immunodeficiency 6 . Use immunoglobulins blood product within 3 month prior vaccination plan use whole study period .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>EV71 Vaccine</keyword>
</DOC>